SeaCrest Wealth Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

SeaCrest Wealth Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-53	Closed	-$26K	–	721
2022 Q2	$26K	Buy	+53	New	+$27.6K	﹤0.01%	1384
2019 Q2	–	Sell	-36	Closed	-$11K	–	661
2019 Q1	$11K	Buy	36 +5	+16%	+$1.35K	﹤0.01%	1486
2018 Q4	$7K	Sell	31 -1	-3%	-$268	﹤0.01%	1583
2018 Q3	$10K	Hold	32	–	–	﹤0.01%	1640
2018 Q2	$9K	Sell	32 -8	-20%	-$2.21K	﹤0.01%	1644
2018 Q1	$10K	Hold	40	–	–	﹤0.01%	1567
2017 Q4	$10K	Buy	+40	New	+$9.69K	﹤0.01%	1583

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SeaCrest Wealth Management's BIO Position: Q3 2022 in Review

SeaCrest Wealth Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2022, closing a stake of 53 shares — an estimated $26K sold.

SeaCrest Wealth Management first reported a position in BIO in Q4 2017 and held it in 7 quarters. The position peaked at $26K in Q2 2022. 484 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

SeaCrest Wealth Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2022 after selling out during the quarter.
SeaCrest Wealth Management sold 53 Bio-Rad Laboratories Class A shares in Q3 2022, an estimated $26K.
SeaCrest Wealth Management first reported a position in Bio-Rad Laboratories Class A in Q4 2017 and held it in 7 quarters.
SeaCrest Wealth Management's Bio-Rad Laboratories Class A position peaked at $26K in Q2 2022.
484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on SeaCrest Wealth Management's 13F filing for Q3 2022, filed 15 Nov 2022.